The role of cardiac magnetic resonance in hypertrophic cardiomyopathy

Revista Portuguesa de Cardiologia

Volumn 29, Issue 1, 2010, Pages 79-93

  Duarte, Sérgio ^a   Bocaert, Jan ^b  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cardiac imaging; Hypertrophic cardiomyopathy; Magnetic resonance imaging; Myocardial hypertrophy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; VERAPAMIL;

CONTRAST ENHANCEMENT; DIASTOLIC DYSFUNCTION; FABRY DISEASE; FRIEDREICH ATAXIA; HEART AMYLOIDOSIS; HEART CANCER; HEART DISEASE; HEART HYPERTROPHY; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEFT VENTRICULAR NON COMPACTION; METABOLIC DISORDER; MITRAL VALVE REGURGITATION; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SARCOIDOSIS; STORAGE DISEASE;

CARDIOMYOPATHY, HYPERTROPHIC; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 77954727267     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Maron BJ, McKenna WJ, Danielson, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;42:1687-713
2. St John Sutton MG, Lie JT, Anderson KR, et al. Histopathological specificity of hypertrophic obstructive cardiomyopathy: myocardial fibre disarray and myocardial fibrosis. Br Heart J 1980;44:433-43
3. Maron BJ et al. Contemporary Definitions and Classification of the Cardiomyopathies. Circulation. 2006;113:1807-1816.
4. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699-1708
5. Maron M, Hauser TH, Dubrow E, Horst T, Kissinger KV, Udelson JE, Manning WJ. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol 2007;100:1293-129
6. Kubo et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol (2007) vol. 49 (25) 2419-26
7. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989;320:749-55 (Pubitemid 19093540)
8. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996;276:199-204
9. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342
10. Choudhury et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. JACC 2002: 2156-64
11. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-785
12. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventriculer outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303 (Pubitemid 36119984)
13. Rickers C et el. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation (2005) vol. 112 (6) 855-61
14. Been M et al. Nuclear magnetic resonance in hypertrophic cardiomyopathy. Br Heart J 1985 54:48-52
15. Soler R et al. Magnetic resonance imaging of apical hypertrophy cardiomyopathy. J Thorac Imaging (1997) 12: 221-225
16. Young et al. Three-dimensional left ventricular deformation in hypertrophic cardiomyopathy. Circulation (1994) vol. 90 (2) 854-67
17. Kramer et al. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation (1994) vol. 90 (1) 186-94
18. Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 1998;97:461-6
19. Schulz-Menger J, Abdel-Aty H, Busjahn A, Wassmuth R, Pilz B., Dietz R, Friedrich M. Left Ventricular Outflow Tract Planimetry by Cardiovascular Magnetic Resonance Differentiates Obstructive from Non-Obstructive Hypertrophic Cardiomyopathy J Cardiovascular Magnetic Resonance (2006) 8, 741-746
20. John AS, Dill T, Brandt RR, et al. Magnetic resonance to assess the aortic valve area in eortic stenosis: how does it compare to current diagnostic standards? J Am Coll Cardiol 2003;42:519-26
21. Kawada et al. Hypertrophic Cardiomyopathy: MR Measurement of Coronary Blood Flow and Vasodilator Flow Reserve in Patients and Healthy Subjects. Radiology 1999 21 129-135
22. Sipola P, Lauerma K, Husso-Saastamoinen M, Kuikka JT, Vanninen E, Laitinen T, Manninen H, Niemi P, Peuhkurinen K, Jaaskelainen P, Laakso M, Kuusisto J, Aronen HJ. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. Radiology 2003; 226: 129-137
23. Kitazume H, Kramer JR, Krauthamer D, El Tobgi S, Proudfit WL, Sones FM. Myocardial bridges in obstructive hypertrophic cardiomyopathy. Am Heart J 1983; 106:131-135 (Pubitemid 13074846)
24. Leschka S et al. Myocardial Bridging: Depiction Rate and Morphology at CT Coronary Angiography - Comparison with Conventional Coronary Angiography. Radiology 2008; 246: 754-762
25. Bogaert J et al. Use of inversion recovery contrast-enhanced MRI for cardiac imaging: spectrum of applications. American Journal of Roentgenology (2004) vol. 182 (3) 609-5
26. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103: 2780-3
27. Bogaert J et al. Original report. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. American Journal of Roentgenology (2003) vol. 180 (4) 981-5
28. Adabag AS et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol (2008) vol. 51 (14) 1369-74
29. Moon JCC, McKenna W, McCrohon JA, et al. Towards clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003;41:1561-7
30. van Dockum et al. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. European Heart Journal (2006) vol. 27 (23) 2833-9
31. van Dockum et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol. 2004;43:27-34.
32. van Dockum et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation (2005) vol. 111(19)2503-8
33. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7:204-214
34. Basavarajaiah S et al. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol (2008) vol. 51 (10) 1033-9
35. Petersen SE, Selvanayagam JB, Francis JM, et al. Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2005; 7:551-558
36. Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G. Contribution of magnetic resonance imaging in the differentiel diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 1998; 136:824-830
37. Rahman JE et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol (2004) vol. 43 (3) 410-5
38. Krombach GA et al. Cardiac Amyloidosis: MR Imaging Findings and T1 Quantification, Comparison With Control Subjects J Magn Reson Imaging 2007; 25:1283-1287
39. Vogelsberg H et al. CMRI in Cardiac Amyloidosis. JACC 2008; 51: 1022-1030
40. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105:1407-1411 (Pubitemid 34263268)
41. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139:1101-1108
42. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24:2151-2155
43. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected petients with systemic sarcoidosis. Circulation 1978; 58:1204-1211
44. Hiraga H, Iwai K, Hiroe M, Omori F, Sekiguchi M, Tachibana T, et al. Guidelines for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases (in Japanese). Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 23-4
45. Smedema JP et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest (2005) vol. 128 (1) 30-5
46. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR 2005; 184:249-254
47. Ohira H et al. Myocardial imaging with (18)F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging (2008) vol. 35 (5) 933-41
48. Parrillo JE. Heart disease and the eosinophil. New Engl J Med 1990; 323:1560-1561
49. Salanitri GC. Endomyocardial fibrosis and intracardiac thrombus occurring in idiopathic hypereosinophilic syndrome. AJR 2005; 184:1432-1433
50. Syed IS et al. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol (2007), doi:10.1016/j.ijcard.2007.01.019
51. Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompection: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol 2000;36:493-500
52. Kohli SK, Pantazis AA, Shah JS, et al. Diagnosis of left-ventricular noncompaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criterie? Eur Heert J 2008; 29:89-95
53. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 2005;46:101-105
54. Monserrat L, Hermide-Prieto M, Fernandez X, Rodriguez I, Dumont C, Cazon L, Cuesta MG, Gonzalez-Juanatey C, Peteiro J, Alvarez N, Penas-Lado M, Castro-Beiras A. Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects. Eur Heart J. Published online ahead of print July 4, 2007
55. Geoffroy G, Barbeau A, Breton G, et al. Clinical description and roentgenologic evaluation of patients with Friedreich ataxia. Can J Neurol Sci. 1976;3:279-286
56. Harding A. Friedreich's atexia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104:589-620 (Pubitemid 12202197)
57. Meyer et al. Cardiomyopathy in Friedreich's Ataxia-Assessment by Cardiac MRI. Movement Disorders 2007; 11: 1615-1622
58. Pasternac A et al. Hypertrophic cardiomyopathy in Friedreich's ataxia: symmetric or asymmetric? Can J Neurol Sci. (1980) vol. 7 (4) 379-82